New York State Common Retirement Fund Has $4.77 Million Stake in Guardant Health, Inc. $GH

New York State Common Retirement Fund lowered its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 27.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 76,283 shares of the company’s stock after selling 28,572 shares during the period. New York State Common Retirement Fund owned approximately 0.06% of Guardant Health worth $4,766,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in GH. TD Waterhouse Canada Inc. increased its stake in Guardant Health by 3.2% during the third quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock valued at $306,000 after acquiring an additional 151 shares during the period. IFP Advisors Inc lifted its position in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares during the period. Main Management ETF Advisors LLC boosted its stake in Guardant Health by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock worth $1,106,000 after buying an additional 348 shares in the last quarter. CWM LLC boosted its stake in Guardant Health by 21.6% during the third quarter. CWM LLC now owns 2,020 shares of the company’s stock worth $126,000 after buying an additional 359 shares in the last quarter. Finally, F m Investments LLC increased its holdings in Guardant Health by 1.2% in the 2nd quarter. F m Investments LLC now owns 39,099 shares of the company’s stock valued at $2,035,000 after buying an additional 471 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Up 3.5%

GH opened at $101.85 on Friday. Guardant Health, Inc. has a 1-year low of $34.88 and a 1-year high of $120.74. The stock has a market capitalization of $12.84 billion, a PE ratio of -31.73 and a beta of 1.63. The firm has a 50-day moving average price of $106.38 and a two-hundred day moving average price of $81.68.

Insider Transactions at Guardant Health

In other news, insider Terilyn J. Monroe sold 55,167 shares of Guardant Health stock in a transaction on Monday, December 1st. The stock was sold at an average price of $105.97, for a total value of $5,846,046.99. Following the completion of the sale, the insider directly owned 20,920 shares of the company’s stock, valued at approximately $2,216,892.40. This trade represents a 72.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Chris Freeman sold 31,452 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.07, for a total value of $3,241,757.64. Following the transaction, the insider directly owned 25,987 shares in the company, valued at $2,678,480.09. This trade represents a 54.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 434,627 shares of company stock worth $45,592,052 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GH shares. Guggenheim lifted their price objective on Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, January 26th. Canaccord Genuity Group raised their target price on Guardant Health from $100.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Thursday, January 22nd. BTIG Research increased their price objective on Guardant Health from $100.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, Evercore set a $105.00 target price on shares of Guardant Health and gave the company an “in-line” rating in a research note on Monday, January 5th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $106.86.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.